Short answer: The three main risks are product risk (incorrect content, contamination, and endotoxin in unregulated product), biological risk (IGF-1 elevation from growth-axis peptides, with no long-term safety data in healthy adults), and clinical risk (no screening for malignancy, pregnancy, kidney disease, or interacting medication). Absolute caution applies with any active or prior cancer.
Who should not use growth-axis peptides
- Active malignancy or a history of cancer.
- Active proliferative retinopathy.
- Pregnancy or breastfeeding.
- Uncontrolled diabetes — these compounds worsen glucose tolerance.
- Anyone unwilling to have IGF-1 monitored.
Product quality
Independent analyses of research-market peptides have found substantial variance from labelled content, bacterial contamination, and endotoxin. Reconstitution and injection technique add further infection risk when done without training.
← Back to peptide therapy: evidence, legality, and safety
Want a straight answer about whether a peptide is right for you? Kindr clinicians will tell you when the evidence supports it — and when it does not.
Start your visit →Not ready? Ask Dot, our free AI menopause companion.
Frequently asked questions
Do peptides cause cancer?
No peptide has been shown to cause cancer in humans. The concern is specific: growth-axis peptides raise IGF-1, and higher IGF-1 is epidemiologically associated with certain cancers. That is a reason for caution and monitoring, not a proven causal link.
What are the common side effects?
For growth-axis peptides: water retention, joint aching, tingling, and impaired glucose tolerance. For incretins: nausea, vomiting, and constipation. For any injectable: injection-site reaction and infection risk.
Peptide therapy: evidence, legality, and safety
Evidence grading, regulation, safety, sourcing, and clinical use. Start anywhere.
Other Kindr symptom hubs
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- BPC-157 — tissue repair peptidePeptide
- GLP-1s in menopauseJournal
- TB-500 — recovery & repairPeptide
- Menopause & weight gainJournal
- GHK-Cu — regenerative copper peptidePeptide
- SemaglutidePeptide
Sources
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022.
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023.
- Falutz J et al. Effects of tesamorelin on visceral adipose tissue. J Acquir Immune Defic Syndr 2010.
- Kingsberg SA et al. Bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019.
- US Food and Drug Administration. Bulk drug substances nominated for use in compounding — 503A and 503B category listings, 2023.
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — preclinical review. Curr Pharm Des (preclinical evidence only).
Educational content only — not a substitute for professional medical advice, diagnosis, or treatment. The severity quiz is a screening aid, not a diagnosis. Reviewed by the Kindr Health clinical team · Last reviewed 2026-07-26.